Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/1781
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rančić N. | en_US |
dc.contributor.author | Vavić N. | en_US |
dc.contributor.author | Cikota-Aleksić B. | en_US |
dc.contributor.author | Magić Z. | en_US |
dc.contributor.author | Momir Mikov | en_US |
dc.contributor.author | Bokonjić D. | en_US |
dc.contributor.author | Šegrt Z. | en_US |
dc.contributor.author | Dragojević-Simić V. | en_US |
dc.date.accessioned | 2019-09-23T10:17:46Z | - |
dc.date.available | 2019-09-23T10:17:46Z | - |
dc.date.issued | 2018-02-01 | - |
dc.identifier.issn | 428450 | en_US |
dc.identifier.uri | https://open.uns.ac.rs/handle/123456789/1781 | - |
dc.description.abstract | © 2018, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Background/Aim. Tacrolimus concentration-dose ratio as a potential therapeutic drug monitoring strategy was suggested to be used for the patients subjected to renal trans-plantation. The aim of this study was examining the relationship between tacrolimus concentration-dose ratio, suggested to be used as a therapeutic drug monitoring strategy and the polymorphisms of genes encoding the most important enzymes, such as CYP3A5 and CYP3A4, as well as the transporter P-glycoprotein, for its metabolism and elimination. Methods. The study was designed as a prospective case series study, in which the unit of monitoring was the outpatient examination of 54 patients subjected to renal transplantation. Genotyping was performed by 7500 Real-Time PCR System by assessing allelic discrimination based on TaqMan® methodology. Results. Patients (n = 13) who were treated with less than 2 mg of tacrolimus/day (0.024 ± 0.006 mg/kg/day) had the tacrolimus concentration-dose ratio larger than 150 ng/mL/mg/kg. In this group, 84.62% patients had CYP3А5 *3*3 allele. All of these patients had CYP3А4 *1*1/*1*1B allele. Regarding ABCB1 C3435T gene, 30.77% of patients had the TT gene variant, while 69.23% of our patients had CC and CT gene variants. Conclusion. Tacrolimus concentration-dose ratio greater than 150 ng/mL/mg/kg is cut-off value in patients subjected to renal transplantation which might point to patients who are poor CYP3A5 metabolizers and/or with dysfunctional P-glycoprotein. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Vojnosanitetski Pregled | en_US |
dc.subject | kidney transplantation | en_US |
dc.subject | tacrolimus | en_US |
dc.subject | dose-response relationship | en_US |
dc.subject | genetic | en_US |
dc.subject | polymorphism | en_US |
dc.title | The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.doi | 10.2298/VSP151230329R | - |
dc.identifier.scopus | 2-s2.0-85042289969 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85042289969 | - |
dc.description.version | Published | en_US |
dc.relation.lastpage | 153 | en_US |
dc.relation.firstpage | 147 | en_US |
dc.relation.issue | 2 | en_US |
dc.relation.volume | 75 | en_US |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
Appears in Collections: | MDF Publikacije/Publications |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.